AZD8848
Phase 2Small molecule
AstraZenecaAZD8848 is one of 88 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 2.
3
Indications
8
Total Trials
0
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
271 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Comparator: Statins
Merck & Co.Phase 3
Immunotherapy
Bristol-Myers SquibbPhase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
Flonase
TevaPhase 3
Asmanex
NovartisPreclinical
Veramyst
GSKPreclinical
Singulair
AstraZenecaPreclinical
HCP1102
Hanmi Pharmaceutical Company LimitedPhase 3
AZD8848
AstraZenecaPhase 2
Xolair
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Allergic Rhinitis2 trials
LCH1 trial
Allergic Asthma1 trial
Biomarkers1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD8848. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company